Vifor Pharma’s hypertension and CKD drug Veltassa meets primary endpoint in phase II study
The study has showed a significantly higher proportion of patients with resistant hypertension (RHTN) and CKD taking Veltassa remained on spironolactone therapy compared against patients taking placebo at